CORDIS · 821558 · H2020
IMMUcan Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts
Coordinator: EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL (BE)
IMMUcan proposes an inclusive and integrated European immuno-oncology platform. IMMUcan will access high-quality human biological material (tissue, blood, stool and saliva) and clinical data from patients with colorectal, lung, head & neck, breast, gastric cancers and immune checkpoints inhibitors failures. We have assembled a strong consortium with ten expert clinical centers, access to large volumes of the required tumor types. IMMUcan will mobilize the majority of academic trials running or expected to start recruiting patients during the project period. A centralized workflow for samples,…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
Co-funding: the European Union contributes €17.8M toward a total project budget of €37.2M — a funding rate of 48%, with the remainder covered by the consortium partners. The project runs over approximately 7.3 years from 2019-03-01 to 2026-06-30.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from BE
see all →- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · H2020 · €178.2M
- SGA1-HE — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101052416 · HORIZON · €153.0M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · H2020 · €150.0M
- SGA2 — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101197135 · HORIZON · €120.0M
- SGA3 — COST - Maximising impact861952 · H2020 · €81.8M
- EIT Digital BP — EIT Digital Sustainable Growth101113245 · HORIZON · €33.7M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
- HBP SGA1 — Human Brain Project Specific Grant Agreement 1720270 · CH · €89.0M
- GrapheneCore1 — Graphene-based disruptive technologies696656 · SE · €89.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the RIA funding scheme.
- What is the EU contribution?
- The European Commission contributes €17.8M toward a total project budget of €37.2M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-JTI-IMI2-2017-13-two-stage.
- Who coordinates the project?
- The project is coordinated by EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL (BE).
- What is the project timeline?
- The project runs from 2019-03-01 to 2026-06-30 — approximately 7.3 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 821558.